TABLE 3.

Peak expiratory flow analysis.

Group	Week0	Week4	Week8	Week12	Week16	Week20
Control	15.30 ± 1.18	15.97 ± 0.60	16.02 ± 0.93	16.22 ± 0.77	16.51 ± 0.72	16.83 ± 0.88
COPD	15.55 ± 1.22	13.40 ± 1.09**	11.62 ± 1.00**	10.75 ± 1.04**	10.42 ± 0.78**	10.89 ± 0.97**
BJF	15.63 ± 0.93	13.75 ± 0.58	11.43 ± 0.91	12.64 ± 1.04##	13.35 ± 1.33##	13.98 ± 1.50##
AICAR	15.44 ± 0.70	13.83 ± 0.98	11.39 ± 0.85	10.93 ± 0.49ΔΔ	10.66 ± 0.92ΔΔ	11.43 ± 0.88ΔΔ
BJF + AICAR	15.88 ± 0.60	13.59 ± 0.58	11.74 ± 0.92	12.60 ± 0.77##	13.57 ± 1.04##▲▲	14.23 ± 0.56##▲▲
APL	15.50 ± 0.59	13.64 ± 0.85	11.24 ± 0.94	12.29 ± 0.90##	13.63 ± 1.08##▲▲	13.57 ± 0.90##

Data are presented as mean ± SD (n = 6 per group). ^∗∗ P < 0.01, ^∗ P < 0.05 vs. control group;^## P < 0.01, ^# P < 0.05 vs. model group; ^ΔΔ P < 0.01, ^Δ P < 0.05 vs. BJF group; ^▲▲ P < 0.01, ^▲ P < 0.05 vs. 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) group; and ^□□ P < 0.01, ^□ P < 0.05 vs. BJF + AICAR group. APL, aminophylline.